GFM
ENTA icon

GF Fund Management’s Enanta Pharmaceuticals ENTA Stock Holding History

GF Fund Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.08K Buy
640
+75
+13% +$1K ﹤0.01% 579
2025
Q4 		$8.91K Buy
565
+117
+26% +$1.49K ﹤0.01% 584
2025
Q3 		$5.36K Sell
448
-77
-15% -$615 ﹤0.01% 607
2025
Q2 		$3.97K Hold
525
– – ﹤0.01% 637
2025
Q1 		$2.9K Buy
525
+80
+18% +$494 ﹤0.01% 642
2024
Q4 		$2.56K Buy
+445
New +$4.27K ﹤0.01% 632

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

GF Fund Management's ENTA Position: Q1 2026 in Review

GF Fund Management increased its Enanta Pharmaceuticals (ENTA) stake by 13% in Q1 2026, buying an estimated $1K and bringing the position to 640 shares worth $8.08K. The position accounts for ﹤0.01% of the portfolio, ranked #579.

GF Fund Management first reported a position in ENTA in Q4 2024 and has held it in 6 quarters since. The position peaked at $8.91K in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • GF Fund Management held 640 shares of Enanta Pharmaceuticals worth $8.08K as of Q1 2026.
  • GF Fund Management bought 75 Enanta Pharmaceuticals shares in Q1 2026, an estimated $1K.
  • Enanta Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #579 holding.
  • GF Fund Management first reported a position in Enanta Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Enanta Pharmaceuticals position peaked at $8.91K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.